CS-7017 + erlotinib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions
Advanced Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Mar 1, 2010 → Apr 1, 2013
NCT ID
NCT01101334About CS-7017 + erlotinib
CS-7017 + erlotinib is a phase 2 stage product being developed by Daiichi Sankyo for Advanced Non-small Cell Lung Cancer (NSCLC). The current trial status is completed. This product is registered under clinical trial identifier NCT01101334. Target conditions include Advanced Non-small Cell Lung Cancer (NSCLC).
What happened to similar drugs?
16 of 20 similar drugs in Advanced Non-small Cell Lung Cancer (NSCLC) were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01199068 | Phase 1 | Completed |
| NCT01101334 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Non-small Cell Lung Cancer (NSCLC)